No connection

Search Results

HLN vs JNJ

HLN
Haleon plc
NEUTRAL
Price
$9.49
Market Cap
$42.18B
Sector
Healthcare
AI Confidence
80%
JNJ
Johnson & Johnson
NEUTRAL
Price
$237.96
Market Cap
$573.46B
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
HLN
18.98
JNJ
21.55
Forward P/E
HLN
15.63
JNJ
18.9
P/B Ratio
HLN
1.9
JNJ
7.03
P/S Ratio
HLN
3.82
JNJ
6.09
EV/EBITDA
HLN
33.5
JNJ
17.81

Profitability

Gross Margin
HLN
64.77%
JNJ
68.08%
Operating Margin
HLN
23.17%
JNJ
23.97%
Profit Margin
HLN
15.11%
JNJ
28.46%
ROE
HLN
10.27%
JNJ
35.03%
ROA
HLN
4.67%
JNJ
8.68%

Growth

Revenue Growth
HLN
0.6%
JNJ
9.1%
Earnings Growth
HLN
92.0%
JNJ
48.6%

Financial Health

Debt/Equity
HLN
0.52
JNJ
0.6
Current Ratio
HLN
0.92
JNJ
1.03
Quick Ratio
HLN
0.68
JNJ
0.69

Dividends

Dividend Yield
HLN
2.01%
JNJ
2.19%
Payout Ratio
HLN
37.08%
JNJ
46.6%

AI Verdict

HLN NEUTRAL

Haleon plc presents a stable fundamental profile with a Piotroski F-Score of 6/9 and a current price of $9.49 that sits comfortably between its Graham Number ($7.49) and Intrinsic Value ($14.75). While the company exhibits strong profitability margins and a healthy debt-to-equity ratio of 0.52, it is hampered by stagnant revenue growth (0.60%) and a completely bearish technical trend (0/100). The massive spike in earnings growth (92%) appears decoupled from top-line performance, suggesting efficiency gains rather than market expansion. Overall, the stock is a value-play with limited immediate momentum.

Strengths
Strong gross margins at 64.77% and operating margins at 23.17%
Conservative leverage with a Debt/Equity ratio of 0.52
Stable financial health indicated by a Piotroski F-Score of 6/9
Risks
Near-zero revenue growth (0.60% YoY) indicating market saturation or lack of pricing power
Severe bearish technical momentum (Technical Trend: 0/100)
Liquidity concerns with a Quick Ratio of 0.68 and Current Ratio of 0.92
JNJ NEUTRAL

JNJ presents a dichotomy between strong profitability and deteriorating fundamental health, evidenced by a weak Piotroski F-Score of 3/9. While the company maintains an impressive ROE of 35.03% and a consistent history of earnings beats, the current price of $237.96 trades at a significant premium to its Graham Number of $91.72. Growth remains robust on a YoY basis, but bearish insider sentiment and a very weak technical trend (10/100) suggest immediate headwinds. The stock is fundamentally sound in terms of earnings power but shows signs of operational inefficiency or declining quality in its deterministic health metrics.

Strengths
Exceptional Return on Equity (ROE) of 35.03%
Strong profit margins (28.46%) and gross margins (68.08%)
Consistent earnings beat track record over 25 quarters
Risks
Weak Piotroski F-Score (3/9) indicating declining fundamental health
Bearish insider activity with $58.35M in net sales and zero buys
Low liquidity indicated by a Quick Ratio of 0.69

Compare Another Pair

HLN vs JNJ: Head-to-Head Comparison

This page compares Haleon plc (HLN) and Johnson & Johnson (JNJ) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI Chat
Markets
Profile